Related Experiment Video
Updated: May 20, 2026
07:57
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Inhibiting HSP90 to treat cancer: a strategy in evolution.
L Whitesell1, S Santagata, N U Lin
1Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA. whitesell@wi.mit.edu
Current Molecular Medicine
|July 19, 2012
Summary
Heat shock protein 90 (HSP90) inhibitors show promise for cancer therapy but have disappointing single-agent activity. Combining HSP90 inhibitors with other agents may improve durable disease control.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Heat shock protein 90 (HSP90) is a molecular chaperone crucial for cancer cell physiology.
- HSP90 inhibitors have been developed with anticancer activity.
- First-generation HSP90 inhibitors show limited efficacy as single agents in clinical trials.
Purpose of the Study:
- To review the progress and challenges in HSP90 inhibitor development for cancer treatment.
- To explore the reasons for the disappointing clinical activity of HSP90 inhibitors.
- To suggest strategies for improving the clinical success of HSP90 inhibitors.
Main Methods:
- Review of existing literature on HSP90 inhibitors and their clinical trials.
- Analysis of the pharmacological properties and limitations of HSP90 inhibitors.
- Discussion of potential therapeutic strategies involving HSP90 inhibitors.
Main Results:
- HSP90 inhibitors are valuable tools for understanding cancer biology.
- Systemic exposure to HSP90 inhibitors may not be sufficiently cytotoxic for many cancers.
- HSP90 inhibitors may enhance the efficacy of other anticancer drugs and overcome resistance.
Conclusions:
- The intrinsic limitations of HSP90 inhibitors may contribute to their poor single-agent activity.
- HSP90 inhibitors could be more effective when used in combination therapy.
- Future clinical development should focus on optimizing HSP90 inhibitor strategies for durable cancer control.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...